Literature DB >> 2049233

Lack of pharmacokinetic interaction between nifedipine, sparteine and phenytoin in man.

J H Schellens1, P A Soons, J H van der Wart, J W Hoevers, D D Breimer.   

Abstract

Nifedipine, sparteine and phenytoin were administered orally to eight healthy subjects separately and as a 'cocktail' on four different occasions to investigate any kinetic interactions. All subjects were extensive metabolizers of sparteine. After drug intake plasma and urine samples were collected up to 32 h and the concentrations of parent drugs and main metabolites were measured. Clearances and formation clearances were not significantly different after single substrate and 'cocktail' administration. Low or non significant correlation coefficients were found between the oxidation of the individual substrates or formation of their metabolites. With this strategy of simultaneous administration of substrates ('cocktail') it appears possible to characterize (and correlate) activities of different cytochrome P-450 isoenzymes, without the disturbing influence of intraindividual variation of drug oxidation with time.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2049233      PMCID: PMC1368386          DOI: 10.1111/j.1365-2125.1991.tb05508.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family.

Authors:  P Vermeij; M D Ferrari; O J Buruma; H Veenema; F A de Wolff
Journal:  Clin Pharmacol Ther       Date:  1988-11       Impact factor: 6.875

2.  The genetic polymorphism of sparteine metabolism.

Authors:  M Eichelbaum; K P Reetz; E K Schmidt; C Zekorn
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908

3.  Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects.

Authors:  J H Schellens; P A Soons; D D Breimer
Journal:  Biochem Pharmacol       Date:  1988-07-01       Impact factor: 5.858

4.  Gas chromatographic determination of sparteine and 2- and 5-dehydrosparteine in plasma and urine.

Authors:  J H Schellens; H H van der Wart; J W Hoevers; D D Breimer
Journal:  J Chromatogr       Date:  1988-09-23

5.  Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a 'cocktail' approach.

Authors:  J H Schellens; J H van der Wart; M Danhof; E A van der Velde; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

6.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

7.  Liquid chromatographic determination of nifedipine in plasma and of its main metabolite in urine.

Authors:  C H Kleinbloesem; J Van Harten; P Van Brummelen; D D Breimer
Journal:  J Chromatogr       Date:  1984-06-08

8.  Influence of enzyme induction and inhibition on the oxidation of nifedipine, sparteine, mephenytoin and antipyrine in humans as assessed by a "cocktail" study design.

Authors:  J H Schellens; J H van der Wart; M Brugman; D D Breimer
Journal:  J Pharmacol Exp Ther       Date:  1989-05       Impact factor: 4.030

9.  Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans.

Authors:  S Fritz; W Lindner; I Roots; B M Frey; A Küpfer
Journal:  J Pharmacol Exp Ther       Date:  1987-05       Impact factor: 4.030

10.  Phenytoin metabolism in subjects with long and short plasma half-lives.

Authors:  A J Glazko; F E Peterson; T Chang; W A Dill; T C Smith; R A Buchanan
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

View more
  3 in total

Review 1.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

Review 2.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

3.  Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.

Authors:  M A Laurent-Kenesi; C Funck-Brentano; J M Poirier; D Decolin; P Jaillon
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.